COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company will meet with the U.S. Food and Drug Administration (FDA) to discuss two remaining issues that the agency has about the use of Oxycyte® in a proposed Phase IIb clinical trial in Traumatic Brain Injury (TBI). The meeting will be requested next week and is expected to be scheduled within 30 days after the agency has received the request. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
